However, although extensive clinical evidence supports the administration of asparaginase therapy in pediatric ALL and the benefit of intensive asparaginase regimens,26, 27 debate continues regarding the optimal dosing and schedule, duration of treatment, indication of front‐line or second‐line asparaginase therapy, or management of toxicities.28, 29. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.